285 related articles for article (PubMed ID: 15607433)
1. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease.
Cooper ME
Am J Hypertens; 2004 Dec; 17(12 Pt 2):31S-38S. PubMed ID: 15607433
[TBL] [Abstract][Full Text] [Related]
2. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
Lassila M; Seah KK; Allen TJ; Thallas V; Thomas MC; Candido R; Burns WC; Forbes JM; Calkin AC; Cooper ME; Jandeleit-Dahm KA
J Am Soc Nephrol; 2004 Aug; 15(8):2125-38. PubMed ID: 15284298
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
Bakris GL; Bank AJ; Kass DA; Neutel JM; Preston RA; Oparil S
Am J Hypertens; 2004 Dec; 17(12 Pt 2):23S-30S. PubMed ID: 15607432
[TBL] [Abstract][Full Text] [Related]
4. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.
Candido R; Forbes JM; Thomas MC; Thallas V; Dean RG; Burns WC; Tikellis C; Ritchie RH; Twigg SM; Cooper ME; Burrell LM
Circ Res; 2003 Apr; 92(7):785-92. PubMed ID: 12623881
[TBL] [Abstract][Full Text] [Related]
5. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
[TBL] [Abstract][Full Text] [Related]
6. Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat.
Sun M; Yokoyama M; Ishiwata T; Asano G
Int J Exp Pathol; 1998 Aug; 79(4):207-22. PubMed ID: 9797717
[TBL] [Abstract][Full Text] [Related]
7. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
8. Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.
Petrica L; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Vlad D; Popescu R; Velciov S; Gluhovschi C; Bob F; Ursoniu S; Petrica M; Jianu DC
J Diabetes Complications; 2015 Mar; 29(2):230-7. PubMed ID: 25511877
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies.
Daroux M; Prévost G; Maillard-Lefebvre H; Gaxatte C; D'Agati VD; Schmidt AM; Boulanger E
Diabetes Metab; 2010 Feb; 36(1):1-10. PubMed ID: 19932633
[TBL] [Abstract][Full Text] [Related]
10. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view.
Chilelli NC; Burlina S; Lapolla A
Nutr Metab Cardiovasc Dis; 2013 Oct; 23(10):913-9. PubMed ID: 23786818
[TBL] [Abstract][Full Text] [Related]
11. AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease.
Jensen LJ; Østergaard J; Flyvbjerg A
Horm Metab Res; 2005 Apr; 37 Suppl 1():26-34. PubMed ID: 15918107
[TBL] [Abstract][Full Text] [Related]
12. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME
Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets.
Farhangkhoee H; Khan ZA; Kaur H; Xin X; Chen S; Chakrabarti S
Pharmacol Ther; 2006 Aug; 111(2):384-99. PubMed ID: 16343639
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).
Oldfield MD; Bach LA; Forbes JM; Nikolic-Paterson D; McRobert A; Thallas V; Atkins RC; Osicka T; Jerums G; Cooper ME
J Clin Invest; 2001 Dec; 108(12):1853-63. PubMed ID: 11748269
[TBL] [Abstract][Full Text] [Related]
16. [Advanced glycation end products and hyperglycaemia].
Omsland TK; Bangstad HJ; Berg TJ; Kolset SO
Tidsskr Nor Laegeforen; 2006 Jan; 126(2):155-8. PubMed ID: 16415936
[TBL] [Abstract][Full Text] [Related]
17. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes.
Joshi D; Gupta R; Dubey A; Shiwalkar A; Pathak P; Gupta RC; Chauthaiwale V; Dutt C
J Cardiovasc Pharmacol; 2009 Jul; 54(1):72-81. PubMed ID: 19546815
[TBL] [Abstract][Full Text] [Related]
18. Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats.
Oturai PS; Christensen M; Rolin B; Pedersen KE; Mortensen SB; Boel E
Metabolism; 2000 Aug; 49(8):996-1000. PubMed ID: 10954016
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease.
Li JH; Huang XR; Zhu HJ; Oldfield M; Cooper M; Truong LD; Johnson RJ; Lan HY
FASEB J; 2004 Jan; 18(1):176-8. PubMed ID: 12709399
[TBL] [Abstract][Full Text] [Related]
20. Novel pathways and therapies in experimental diabetic atherosclerosis.
Koulis C; de Haan JB; Allen TJ
Expert Rev Cardiovasc Ther; 2012 Mar; 10(3):323-35. PubMed ID: 22390805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
